Saturday, November 14, 2026

Financial Markets

2 articles

Figure Technology's AAA Blockchain Rating Opens a New Era for Global Tokenized Debt Markets

Figure Technology's AAA Blockchain Rating Opens a New Era for Global Tokenized Debt Markets

A US fintech has secured the first-ever AAA credit rating for a blockchain-based securitization product, a milestone that analysts say could accelerate the adoption of tokenized debt instruments across international capital markets. The achievement by Figure Technology Solutions removes a key fiduciary barrier that has long kept institutional investors worldwide on the sidelines of real-world asset tokenization. Industry observers expect the breakthrough to trigger a wave of similar filings from

ViaNews Editorial Team•
First AAA-Rated Blockchain Securitization Marks a Global Turning Point for Institutional DeFi

First AAA-Rated Blockchain Securitization Marks a Global Turning Point for Institutional DeFi

A landmark AAA credit rating on a blockchain-based loan securitization by US lender Figure Technology Solutions signals that global institutional capital — long barred from decentralised finance by the absence of investment-grade ratings — may finally be ready to enter the space. The development carries implications far beyond Wall Street, touching sovereign wealth funds, European insurance regulators, and emerging market fintech ecosystems seeking credible capital market infrastructure.

ViaNews Editorial Team•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com